Pipeline

HomePipeline

Initial Targeted Indications

Indication Targeted Subgroup Formulation Unique selling point (USP)
Body Sculpting Double chin Injectable Significantly less inflammation than currently marketed injectable; Single treatment efficacy expected to be sufficient in majority of clients
Central abdominal bulge Injectable No available injectable
Dupuytren’s Disease Progressive contractures post hand surgery or Xiaflex injection(s) Injectable sustained release Large unmet medical need for effective disease modifying treatment
Progressive contractures post hand surgery or Xiaflex injection(s) Topical Large market for effective treatment that can be patient-administered

Additional Development Opportunities

Indication Targeted Subgroup Formulation Unique selling point (USP)
Uncontrolled Type 2 diabetes mellitus (T2DM) Overweight and requiring insulin Injectable Unique short term treatment reduces body weight and improves glycemic control and reduces cardiovascular risk (CV) factors
NASH Obese with metabolic syndrome Injectable / Oral Improvement in liver parameters, including fibrosis and significant reduction in CV risk factors

Call

240-313-5714

Call Us

Email

contact@dalebiotech.com

Contact Form

Offices

410 Caymus Street
Kennedale, TX 76060 USA
22 North Mulberry St., Suite 318 Hagerstown, MD 21740 USA

Contact Hours

09:00 - 17:00 ET